Featured Story

Scientists ID a new approach to treating nicotine addiction

Nicotine addiction has already defeated a number of companies that have tried to come up with an effective cure. Now scientists at the University of Massachusetts Medical School and The Scripps Research Institute say they have identified a particular circuit in the brain that promotes anxiety during withdrawal--offering a new approach in R&D.

AbbVie, Infinity tout preclinical evidence of a cancer combo's potential

Preclinical research can play a big role in pursuing new combination therapies. Case in point: Infinity's duvelisib (IPI-145). Partnered with AbbVie, investigators have gone back to the lab to help establish what the PI3K-delta/gamma inhibitor might best be paired with. And not too surprisingly they concluded that AbbVie's BCL-2 protein inhibitor venetoclax (ABT-199) might make a good match.

MD Anderson takes experimental lung cancer drug into the clinic

What's the next step for researchers focused on PD-1 and PD-L1, the two big targets for checkpoint inhibitors that are now hitting the oncology market? Scientists at The University of Texas MD Anderson Cancer Center offered one potential pathway, pointing to the role of p53 in spurring the advance of non-small cell lung cancer. And they're now working on an experimental lung cancer drug that has shown promise in a mouse study.

Yale cancer group refines an antibody approach to targeting cancer cells

Building on insights that antibodies generated by lupus can also kill cancer cells, investigators at Yale School of Medicine say that they have found a way to engineer these antibodies into a more efficient weapon.

Seeking a drug cocktail, CSHL team points to a new pathway for breast cancer

Investigators believe that they have found a new approach to treating HER2-positive breast cancer in a class of enzymes called protein tyrosine phosphatases, or PTPs, which plays a role in cell proliferation.


From Our Sister Sites


Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.


Veracyte is selling $40 million of its common stock in a private placement to generate some cash for R&D, adding fuel to its engine as it inks new deals and looks to expand its portfolio.